Metronomic chemotherapy dosing-schedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth

Thomas Lam, John W. Hetherington, John Greenman, Samantha Little, Anthony Maraveyas

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The effects of ‘metronomic'or extended chemotherapy dosing schedules (ECS) are mediated through poorly understood anti-angiogenic mechanisms. ECS combined with biological anti-angiogenic agents have produced promising pre-clinical results. Materials and Methods. We have expanded the list of agents with an in vitro ECS profile to include the methylating agent temozolomide (Temodal®) and the anti-mitotic agent estramustine (Estracyt®). These agents were also combined with a specific anti-angiogenic inhibitor IMC-1C11 and a non-specific agent with anti-angiogenic properties, Compound 5h. The in vitro HUVEC ECS model system was optimised and cell proliferation assays undertaken. Results. As a single agent, estramustine inhibited endothelial cell proliferation with an IC50 of 4.5 µM and was active at 10–33% of the maximum tolerated dose (MTD) from clinical schedules, whilst temozolomide had IC50 of 6.6 µM and was active at 1–6% of MTD. In combination, significant synergy was seen with IMC-1C11 in combination with either drug, whilst modest additive effects were observed with Compound 5h. None of the combinations resulted in significant cytotoxicity or apoptosis. Discussion. The results show that ECS of temozolomide and estramustine can be significantly enhanced when combined with specific anti-angiogenic inhibitors in an in vitro HUVEC system.
Original languageEnglish
Pages (from-to)1169-1177
Number of pages9
JournalActa Oncologica
Volume46
Issue number8
DOIs
Publication statusPublished - 2007

Fingerprint

temozolomide
Estramustine
Umbilicus
Vascular Endothelial Growth Factor Receptor-2
Appointments and Schedules
Endothelial Cells
Drug Therapy
Antibodies
Growth
Angiogenesis Inhibitors
Maximum Tolerated Dose
Inhibitory Concentration 50
Cell Proliferation
Apoptosis

Cite this

Metronomic chemotherapy dosing-schedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth. / Lam, Thomas; Hetherington, John W.; Greenman, John; Little, Samantha; Maraveyas, Anthony.

In: Acta Oncologica, Vol. 46, No. 8, 2007, p. 1169-1177.

Research output: Contribution to journalArticle

@article{f1f653f0ee8a40c9a1b3873bdd4854f3,
title = "Metronomic chemotherapy dosing-schedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth",
abstract = "The effects of ‘metronomic'or extended chemotherapy dosing schedules (ECS) are mediated through poorly understood anti-angiogenic mechanisms. ECS combined with biological anti-angiogenic agents have produced promising pre-clinical results. Materials and Methods. We have expanded the list of agents with an in vitro ECS profile to include the methylating agent temozolomide (Temodal{\circledR}) and the anti-mitotic agent estramustine (Estracyt{\circledR}). These agents were also combined with a specific anti-angiogenic inhibitor IMC-1C11 and a non-specific agent with anti-angiogenic properties, Compound 5h. The in vitro HUVEC ECS model system was optimised and cell proliferation assays undertaken. Results. As a single agent, estramustine inhibited endothelial cell proliferation with an IC50 of 4.5 µM and was active at 10–33{\%} of the maximum tolerated dose (MTD) from clinical schedules, whilst temozolomide had IC50 of 6.6 µM and was active at 1–6{\%} of MTD. In combination, significant synergy was seen with IMC-1C11 in combination with either drug, whilst modest additive effects were observed with Compound 5h. None of the combinations resulted in significant cytotoxicity or apoptosis. Discussion. The results show that ECS of temozolomide and estramustine can be significantly enhanced when combined with specific anti-angiogenic inhibitors in an in vitro HUVEC system.",
author = "Thomas Lam and Hetherington, {John W.} and John Greenman and Samantha Little and Anthony Maraveyas",
year = "2007",
doi = "10.1080/02841860701373603",
language = "English",
volume = "46",
pages = "1169--1177",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Metronomic chemotherapy dosing-schedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth

AU - Lam, Thomas

AU - Hetherington, John W.

AU - Greenman, John

AU - Little, Samantha

AU - Maraveyas, Anthony

PY - 2007

Y1 - 2007

N2 - The effects of ‘metronomic'or extended chemotherapy dosing schedules (ECS) are mediated through poorly understood anti-angiogenic mechanisms. ECS combined with biological anti-angiogenic agents have produced promising pre-clinical results. Materials and Methods. We have expanded the list of agents with an in vitro ECS profile to include the methylating agent temozolomide (Temodal®) and the anti-mitotic agent estramustine (Estracyt®). These agents were also combined with a specific anti-angiogenic inhibitor IMC-1C11 and a non-specific agent with anti-angiogenic properties, Compound 5h. The in vitro HUVEC ECS model system was optimised and cell proliferation assays undertaken. Results. As a single agent, estramustine inhibited endothelial cell proliferation with an IC50 of 4.5 µM and was active at 10–33% of the maximum tolerated dose (MTD) from clinical schedules, whilst temozolomide had IC50 of 6.6 µM and was active at 1–6% of MTD. In combination, significant synergy was seen with IMC-1C11 in combination with either drug, whilst modest additive effects were observed with Compound 5h. None of the combinations resulted in significant cytotoxicity or apoptosis. Discussion. The results show that ECS of temozolomide and estramustine can be significantly enhanced when combined with specific anti-angiogenic inhibitors in an in vitro HUVEC system.

AB - The effects of ‘metronomic'or extended chemotherapy dosing schedules (ECS) are mediated through poorly understood anti-angiogenic mechanisms. ECS combined with biological anti-angiogenic agents have produced promising pre-clinical results. Materials and Methods. We have expanded the list of agents with an in vitro ECS profile to include the methylating agent temozolomide (Temodal®) and the anti-mitotic agent estramustine (Estracyt®). These agents were also combined with a specific anti-angiogenic inhibitor IMC-1C11 and a non-specific agent with anti-angiogenic properties, Compound 5h. The in vitro HUVEC ECS model system was optimised and cell proliferation assays undertaken. Results. As a single agent, estramustine inhibited endothelial cell proliferation with an IC50 of 4.5 µM and was active at 10–33% of the maximum tolerated dose (MTD) from clinical schedules, whilst temozolomide had IC50 of 6.6 µM and was active at 1–6% of MTD. In combination, significant synergy was seen with IMC-1C11 in combination with either drug, whilst modest additive effects were observed with Compound 5h. None of the combinations resulted in significant cytotoxicity or apoptosis. Discussion. The results show that ECS of temozolomide and estramustine can be significantly enhanced when combined with specific anti-angiogenic inhibitors in an in vitro HUVEC system.

U2 - 10.1080/02841860701373603

DO - 10.1080/02841860701373603

M3 - Article

VL - 46

SP - 1169

EP - 1177

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 8

ER -